Manufacturer of Controlled Substances; Notice of Application

---
identifier: "/us/fr/2011-2288"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Manufacturer of Controlled Substances; Notice of Application"
title_number: 0
title_name: "Federal Register"
section_number: "2011-2288"
section_name: "Manufacturer of Controlled Substances; Notice of Application"
positive_law: false
currency: "2011-02-02"
last_updated: "2011-02-02"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Justice Department"
document_number: "2011-2288"
document_type: "notice"
publication_date: "2011-02-02"
agencies:
  - "Justice Department"
  - "Drug Enforcement Administration"
fr_citation: "76 FR 5829"
fr_volume: 76
---


#  Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 25, 2010, AMRI Rensselaer, Inc., 33 Riverside Avenue, Rensselaer, New York 12144, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

| Drug | Schedule |
| --- | --- |
| Marihuana (7360) | I |
| Tetrahydrocannabinols (7370) | I |
| Amphetamine (1100) | II |
| Lisdexamfetamine (1205) | II |
| Methylphenidate (1724) | II |
| Pentobarbital (2270) | II |
| Meperidine (9230) | II |
| Fentanyl (9801) | II |

The company plans to manufacture bulk controlled substances for use in product development and for distribution to its customers.

In reference to drug code 7360 (Marihuana), the company plans to bulk manufacture cannabidiol as a synthetic intermediate. This controlled substance will be further synthesized to bulk manufacture a synthetic THC (7370). No other activity for this drug code is authorized for this registration.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than April 4, 2011.

Dated: January 18, 2011.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.